Active — Not RecruitingNot Applicable

Trial of Preemptive Pharmacogenetics in Underserved Patients

United States492 participantsStarted 2022-08-01

Plain-language summary

This proposed research is relevant to human health because preemptive clinical pharmacogenetic testing may improve the personalization of drug therapy which should improve patient outcomes. Better understanding of the effectiveness and feasibility of preemptive clinical pharmacogenetic testing will inform when and how this innovative healthcare technology is implemented into clinical care. To ensure equitable dissemination in all patient populations, such data is also needed in racial minorities and other traditionally underserved populations. The combined proposed research are relevant to the parts of the NIH's mission pertaining to protecting and improving health and developing scientific human resources that will ensure the Nation's capability to prevent and treat disease.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults \> 18 years of age * at least 3 active prescriptions documented within medical records * Experienced a change to an active prescription within the past 8 months, defined by: * Addition of a new medication * Change in the dose of a current medication * Diagnosis of any condition that could be treated with a medication that can be informed by the pharmacogenetic testing panel. This will likely include: * generalized depression or anxiety disorder * gastroesophageal reflux disorder * erosive esophagitis * gastric ulcer * acute coronary syndrome * chronic pain * surgery (orthopedic, gastrointestinal, cardiovascular etc.) * osteoarthritis * Dyslipidemia * Heart failure * Deep vein thrombosis * Atrial fibrillation * Moderate to severe trauma * stroke * hypercholesterolemia * conditions requiring chronic anticoagulation Exclusion Criteria: * Any history of previous pharmacogenetic testing * Any medical condition that would prohibit the ability to answer study questions * History of Allogenic stem cell or liver transplant * History of chronic kidney dialysis * Life expectancy less than 12 months

What they're measuring

Change in Patient Treatment Satisfaction Measured by the Treatment Satisfaction Questionnaire for Medication (TSQM)

Timeframe: 12-14 months

Trial details

NCT IDNCT05141019

SponsorUniversity of Florida

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-09-08